Release Date: 23-Jan-2025
CKD702 is an innovative tetravalent, bispecific antibody developed by Chong Kun Dang Pharmaceutical with potential antineoplastic activity. This antibody is designed to target two critical cell surface receptors involved in tumor cell proliferation: epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR or c-Met). The structure of CKD702 consists of a single-chain variable fragment (scFv) targeting EGFR, which is fused to the C-terminus of an immunoglobulin G1 (IgG1) antibody targeting c-Met. This design enables CKD702 to simultaneously bind to the extracellular domains of both wild-type and certain mutant forms of EGFR and c-Met on cancer cells, offering a targeted and more effective therapeutic approach for cancers driven by these receptors.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
Upon administration, CKD702 blocks the activation of both EGFR- and c-Met-mediated signaling pathways. The antibody prevents receptor phosphorylation, a crucial step in the activation of these pathways that drive tumor cell proliferation and survival. By inhibiting this phosphorylation, CKD702 disrupts the signaling cascades that promote tumor growth. Additionally, the binding of CKD702 to these receptors triggers receptor degradation, which further suppresses EGFR- and c-Met-mediated signaling, ultimately inhibiting the proliferation of tumor cells.
EGFR and c-Met are frequently upregulated or mutated in a variety of tumor cell types, making them key drivers of oncogenesis in many cancers. The ability of CKD702 to target and inhibit both of these receptors simultaneously is a significant advantage, as it addresses two critical mechanisms of tumor growth and resistance to therapy. By blocking the signaling from both EGFR and c-Met, CKD702 offers the potential for enhanced anti-tumor activity compared to therapies targeting just one of these receptors.
Currently, CKD702 is undergoing Phase 2 clinical trials for the treatment of gastric cancer, a malignancy often associated with poor prognosis and limited treatment options. If successful, CKD702 could provide a new, more effective therapeutic strategy for patients with gastric cancer and other tumors characterized by EGFR and c-Met overexpression.